Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 2/2017

Open Access 01-06-2017

Antiplatelet agents for cancer treatment: a real perspective or just an echo from the past?

Authors: Marek Z. Wojtukiewicz, Dominika Hempel, Ewa Sierko, Stephanie C. Tucker, Kenneth V. Honn

Published in: Cancer and Metastasis Reviews | Issue 2/2017

Login to get access

Abstract

The association between coagulation and cancer development has been observed for centuries. However, the connection between inflammation and malignancy is also well-recognized. The plethora of evidence indicates that among multiple hemostasis components, platelets play major roles in cancer progression by providing surface and granular contents for several interactions as well as behaving like immune cells. Therefore, the anticancer potential of anti-platelet therapy has been intensively investigated for many years. Anti-platelet agents may prevent cancer, decrease tumor growth, and metastatic potential, as well as improve survival of cancer patients. On the other hand, there are suggestions that antiplatelet treatment may promote solid tumor development in a phenomenon described as “cancers follow bleeding.” The controversies around antiplatelet agents justify insight into the subject to establish what, if any, role platelet-directed therapy has in the continuum of anticancer management.
Literature
1.
Sierko, E., & Wojtukiewicz, M. Z. (2007). Inhibition of platelet function: does it offer a chance of better cancer progression control? Seminars in Thrombosis and Hemostasis, 33(7), 712–721.PubMedCrossRef
2.
Menter, D. G., Tucker, S. C., Kopetz, S., Sood, A. K., Crissman, J. D., & Honn, K. V. (2014). Platelets and cancer: a casual or causal relationship: revisited. Cancer and Metastasis Reviews, 33(1), 231–269.PubMedPubMedCentralCrossRef
3.
Wojtukiewicz, M. Z., Hempel, D., Sierko, E., Tucker, S. C., & Honn, K. V. (2016). Thrombin - unique coagulation system protein with multifaceted impacts on cancer and metastasis. Cancer and Metastasis Reviews, 35, 213–233.PubMedCrossRef
4.
Choe, K. S. C. J., Chan, J. M., Carroll, P. R., D’Amico, A. V., & Liauw, S. L. (2012). Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. Journal of Clinical Oncology, 30(28), 3540–3544.PubMedPubMedCentralCrossRef
5.
Gerotziafas, G. T. P. C., Hatmi, M., Samama, M. M., & Elalamy, I. (2008). Clinical studies with anticoagulants to improve survival in cancer patients. Pathophysiology of Haemostasis and Thrombosis, 36(3–4), 204–211.PubMed
6.
Sekiguchi, T., Takemoto, A., Takagi, S., Takatori, K., Sato, S., Takami, M., & Fujita, N. (2016). Targeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasis. Oncotarget, 7(4), 3934–3946.PubMedCrossRef
7.
Holmes, C. E., Levis, J. E., Schneider, D. J., Bambace, N. M., Sharma, D., Lal, I., et al. (2016). Platelet phenotype changes associated with breast cancer and its treatment. Platelets, 27(7), 703–711.PubMedCrossRef
8.
Ho-Tin-Noé, B., Goerge, T., & Wagner, D. D. (2009). Platelets: guardians of tumor vasculature. Cancer Research, 69(14), 5623–5626.PubMedCrossRef
9.
Ho-Tin-Noé, B., Goerge, T., Cifuni, S. M., Duerschmied, D., & Wagner, D. D. (2008). Platelet granule secretion continuously prevents intratumor hemorrhage. Cancer Research, 68(16), 6851–6858.PubMedPubMedCentralCrossRef
10.
Palumbo, J. S., Talmage, K. E., Massari, J. V., La Jeunesse, C. M., Flick, M. J., Kombrinck, K. W., et al. (2005). Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood, 105, 178.PubMedCrossRef
11.
12.
Lian, L., Li, W., Li, Z. Y., Mao, Y. X., Zhang, Y. T., Zhao, Y. M., et al. (2013). Inhibition of MCF-7 breast cancer cell-induced platelet aggregation using a combination of antiplatelet drugs. Oncology Letters, 5(2), 675–680.PubMed
13.
Wojtukiewicz, M. Z., Hempel, D., Sierko, E., Tucker, S. C., & Honn, K. V. (2015). Protease-activated receptors (PARs)--biology and role in cancer invasion and metastasis. Cancer and Metastasis Reviews, 34(4), 775–796.PubMedPubMedCentralCrossRef
14.
Takemoto, A., Okitaka, M., Takagi, S., Takami, M., Sato, S., Nishio, M., et al. (2017). A critical role of platelet TGF-β release in podoplanin-mediated tumour invasion and metastasis. Scientific Report, 7, 42186. doi:10.​1038/​srep42186.CrossRef
15.
Lowe, K. L., Navarro-Nunez, L., & Watson, S. P. (2012). Platelet CLEC-2 and podoplanin in cancer metastasis. Thrombosis Research, 129(Suppl 1), S30–S37.PubMedCrossRef
16.
Umar, A., Steele, V. E., Menter, D. G., & Hawk, E. T. (2016). Mechanisms of nonsteroidal anti-inflammatory drugs in cancer prevention. Seminars in Oncology, 43(1), 65–77.PubMedCrossRef
17.
Shiao, J., Thomas, K. M., Rahimi, A. S., Rao, R., Yan, J., Xie, X. J., et al. (2017). Aspirin/antiplatelet agent use improves disease-free survival and reduces the risk of distant metastases in stage II and III triple-negative breast cancer patients. Breast Cancer Research and Treatment, 161(3), 463–471.PubMedCrossRef
18.
Guillem-Llobat, P., Dovizio, M., Bruno, A., Ricciotti, E., Cufino, V., Sacco, A., et al. (2016). Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells. Oncotarget, 7(22), 32462–32477.PubMedPubMedCentralCrossRef
19.
Mitrugno, A., Sylman, J. L., Ngo, A. T., Pang, J., Sears, R. C., Williams, C. D., & McCarty, O. J. (2017). Aspirin therapy reduces the ability of platelets to promote colon and pancreatic cancer cell proliferation: implications for the oncoprotein c-MYC. American Journal of Physiology. Cell Physiology, 312(2), C176–C189.PubMedCrossRef
20.
Lee, P. C., Yeh, C. M., Hu, Y. W., Chen, C. C., Liu, C. J., Su, C. W., et al. (2016). Antiplatelet therapy is associated with a better prognosis for patients with hepatitis B virus-related hepatocellular carcinoma after liver resection. Annals of Surgical Oncology, 23(Suppl 5), 874–883.PubMedCrossRef
21.
Furlan, C., Steffan, A., Polesel, J., Trovo, M., Gobitti, C., Vaccher, E., et al. (2015). Lower platelet counts and antiplatelet therapy independently predict better outcomes in patients with head and neck squamous cell carcinoma: a retrospective analysis. Biomarker Research, 3(25), 1–3.
22.
Downer, M.K., Allard, C.B., Preston, M.A., Gazian, J.M., Stampfer, M.J., Mucci, L.A. et al. (2017). Regular Aspirin Use and the Risk of Lethal Prostate Cancer in the Physicians’ Health Study. European Urology Feb 8. pii: S0302–2838(17)30069–6. doi:10.​1016/​j.​eururo.​2017.​01.​044.
23.
Holmes, M. D., Chen, W. Y., Li, L., Hertzmark, E., Spiegelman, D., & Hankinson, S. E. (2010). Aspirin intake and survival after breast cancer. Journal of Clinical Oncology, 28(9), 1467–1472.PubMedPubMedCentralCrossRef
24.
Rothwell, P. M. F. F., Belch, J. F., Ogawa, H., Warlow, C. P., & Meade, T. W. (2011). Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet, 377(9759), 31–41.PubMedCrossRef
25.
Leader, A., Zelikson-Saporta, R., Pereg, D., Spectre, G., Rozovski, U., Raanani, P. et al. (2017). The Effect of Combined Aspirin and Clopidogrel Treatment on Cancer Incidence. American Journal Medicine, Feb 14. doi:10.​1016/​j.​amjmed.​2017.​01.​022.
26.
Cook, N. R., Lee, I. M., Gaziano, J. M., Gordon, D., Ridker, P. M., Manson, J. E., et al. (2005). Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. Journal of the American Medical Association, 294(1), 47–55.PubMedCrossRef
27.
28.
Kodela, R., Chattopadhyay, M., Velázquez-Martínez, C. A., & Kashfi, K. (2015). NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid has enhanced chemo-preventive properties compared to aspirin, is gastrointestinal safe with all the classic therapeutic indications. Biochemical Pharmacology, 98(4), 564–572.PubMedPubMedCentralCrossRef
29.
Serebruany, V. L., Cherepanov, V., Cabrera-Fuentes, H. A., & Kim, M. H. (2015). Solid cancers after antiplatelet therapy: confirmations, controversies, and challenges. Thrombosis and Haemostasis, 114(6), 1104–1112.PubMedCrossRef
30.
Serebruany, V. L., Cherepanov, V., Golukhova, E. Z., & Kim, M. H. (2015). The dual antiplatelet therapy trial after the FDA update: noncardiovascular deaths, cancer and optimal treatment duration. Cardiology, 132(2), 74–80.PubMedCrossRef
31.
Serebruany, V. L., Tomek, A., & Kim, M. H. (2015). Survival after solid cancers in antithrombotic trials. American Journal of Cardiology, 116(6), 969–972.PubMedCrossRef
32.
Hicks, B. M., Murray, L. J., Hughes, C., & Cardwell, C. R. (2015). Clopidogrel use and cancer-specific mortality: a population-based cohort study of colorectal, breast and prostate cancer patients. Pharmacoepidemiology and Drug Safety, 24(8), 830–840.PubMedCrossRef
33.
Tranum, B. L., & Haut, A. (1974). Thrombocytosis: platelet kinetics in neoplasia. Journal of Laboratory and Clinical Medicine, 84(5), 615–619.PubMed
34.
Sharma, D., Brummel-Ziedins, K. E., Bouchard, B. A., & Holmes, C. E. (2014). Platelets in tumor progression: a host factor that offers multiple potential targets in the treatment of cancer. Journal of Cellular Physiology, 229(8), 1005–1115.PubMedCrossRef
35.
Li, R., Ren, M., Chen, N., Luo, M., Deng, X., Xia, J., et al. (2014). Presence of intratumoral platelets is associated with tumor vessel structure and metastasis. BioMed Center Cancer, 14, 167. doi:10.​1186/​1471-2407-14-167.
36.
Gasic, G. J., Gasic, T. B., & Stewart, C. C. (1968). Antimetastatic effects associated with platelet reduction. Proceedings of the National Academy of Sciences, 61, 46–52.CrossRef
37.
Allensworth, S. K., Langstraat, C. L., Martin, J. R., Lemens, M. A., McGree, M. E., Weaver, A. L., et al. (2013). Evaluating the prognostic significance of preoperative thrombocytosis in epithelial ovarian cancer. Gynecologic Oncology, 130(3), 499–504.PubMedPubMedCentralCrossRef
38.
Karpatkin, S., Pearlstein, E., Salk, P. L., & Yogeeswaran, G. (1981). Role of platelets in tumor cell metastases. Annals of the New York Academy of Sciences, 370, 101–118.PubMedCrossRef
39.
Rachidi, S., Wallace, K., Day, T. A., Alberg, A. J., & Li, Z. (2014). Lower circulating platelet counts and antiplatelet therapy independently predict better outcomes in patients with head and neck squamous cell carcinoma. Journal of Hematology & Oncology, 27(7), 65. doi:10.​1186/​s13045-014-0065-5.CrossRef
40.
Jacobsen, J., Grankvist, K., Rasmuson, T., & Ljungberg, B. (2002). Prognostic importance of serum vascular endothelial growth factor in relation to platelet and leukocyte counts in human renal cell carcinoma. European Journal of Cancer Prevention, 11(3), 245–252.PubMedCrossRef
41.
Steele, M., & Voutsadakis, I. A. (2017). Pre-treatment platelet counts as a prognostic and predictive factor in stage II and III rectal adenocarcinoma. World Journal Gastrointestinal Oncology, 9(1), 42–49.CrossRef
42.
Mantas, D., Kostakis, I. D., Machairas, N., & Markopoulos, C. (2016). White blood cell and platelet indices as prognostic markers in patients with invasive ductal breast carcinoma. Oncology Letters, 12(2), 1610–1614.PubMedPubMedCentral
43.
Bottsford-Miller, J., Choi, H. J., Dalton, H. J., Stone, R. L., Cho, M. S., Haemmerle, M., et al. (2015). Differential platelet levels affect response to taxane-based therapy in ovarian cancer. Clinical Cancer Research, 21(3), 602–610.PubMedCrossRef
44.
Shen, X. M., Xia, Y. Y., Lian, L., Zhou, C., Li, X. L., Han, S. G., et al. (2016). Mean platelet volume provides beneficial diagnostic and prognostic information for patients with resectable gastric cancer. Oncology Letters, 12(4), 2501–2506.PubMedPubMedCentral
45.
46.
Zhao, Q. T., Yuan, Z., Zhang, H., Zhang, X. P., Wang, H. E., Wang, Z. K., & Duan, G. C. (2016). Prognostic role of platelet to lymphocyte ratio in non-small cell lung cancers: a meta-analysis including 3,720 patients. International Journal of Cancer, 139(1), 164–170.PubMedCrossRef
47.
Zhou, X., Du, Y., Huang, Z., Xu, J., Qiu, T., Wang, J., Wang, T., et al. (2014). Prognostic value of PLR in various cancers: a meta-analysis. PloS One, 9(6), e101119.PubMedPubMedCentralCrossRef
48.
49.
Mezouar, S., Frère, C., Darbousset, R., Mege, D., Crescence, L., Dignat-George, F., Panicot-Dubois, L., et al. Role of platelets in cancer and cancer-associated thrombosis: experimental and clinical evidences. Thrombosis Research, 139, 65–76.
50.
Bergmann, S., & Hammerschmidt, S. (2007). Fibrinolysis and host response in bacterial infections. Thrombosis and Haemostasis, 98(3), 512–520.PubMed
51.
Chauhan, A.S., Kumar, M., Chaudhary, S., Patidar, A., Dhiman, A., Sheokand, N., et al. (2017). Moonlighting glycolytic protein glyceraldehyde-3-phosphate dehydrogenase (GAPDH): an evolutionarily conserved plasminogen receptor on mammalian cells. Federation of American Societies for Experimental Biology, Mar 15. pii: fj.201600982R.
52.
Cicero, L. A., Raposo, G., & Zhang, H. G. (2013). The cell biology of exosomes: historical and perspectives, Emerging concepts of tumor exosome–mediated cell-cell communication. New York: Springer.
53.
54.
Riedl, J., Kaider, A., Marosi, C., Prager, G. W., Eichelberger, B., Assinger, A., et al. (2017). Decreased platelet reactivity in patients with cancer is associated with high risk of venous thromboembolism and poor prognosis. Thrombosis and Haemostasis, 117(1), 90–98.PubMedCrossRef
55.
Dashevsky, O., Varon, D., & Brill, A. (2009). Platelet-derived microparticles promote invasiveness of prostate cancer cells via upregulation of MMP-2 production. International Journal of Cancer, 124(8), 1773–1777.PubMedCrossRef
56.
Hu, Q., Wang, M., Cho, M. S., Wang, C., Nick, A. M., Thiagarajan, P., et al. (2016). Lipid profile of platelets and platelet-derived microparticles in ovarian cancer. Biochimica et Biophysica Acta Clinical, 6, 76–81.PubMedPubMedCentral
57.
Ren, J. G., Zhang, W., Liu, B., Man, Q. W., Xiong, X. P., Li, C., et al. (2016). Clinical significance and roles in angiogenesis of circulating microparticles in oral cancer. Journal of Dental Research, 95(8), 860–867.PubMedCrossRef
58.
Żmigrodzka, M., Guzera, M., Miśkiewicz, A., Jagielski, D., & Winnicka, A. (2016). The biology of extracellular vesicles with focus on platelet microparticles and their role in cancer development and progression. Tumor Biology, 37(11), 14391–14401.PubMedPubMedCentralCrossRef
59.
Helley, D., Banu, E., Bouziane, A., Banu, A., Scotte, F., Fischer, A. M., & Oudard, S. (2009). Platelet microparticles: a potential predictive factor of survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy. European Urology, 56(3), 479–484.PubMedCrossRef
60.
Heinmöller, E., Weinel, R. J., Heidtmann, H. H., Salge, U., Seitz, R., Schmitz, I., et al. (1996). Studies on tumor-cell-induced platelet aggregation in human lung cancer cell lines. Cancer Research and Clinical Oncology, 122(12), 735–744.PubMedCrossRef
61.
Alonso-Escolano, D., Strongin, A. Y., Chung, A. W., Deryugina, E. I., & Radomski, M. W. (2004). Membrane type-1 matrix metalloproteinase stimulates tumor cell-induced platelet aggregation: role of receptor glycoproteins. British Journal of Pharmacology, 141(2), 241–252.PubMedCrossRef
62.
Yan, M., & Jurasz, P. (2016). The role of platelets in the tumor microenvironment: from solid tumors to leukemia. Biochimica et Biophysica Acta, 1863(3), 392–400.PubMedCrossRef
63.
Im, J. H., Fu, W., Wang, H., Bhatia, S. K., Hammer, D. A., Kowalska, M. A., & Muschel, R. J. (2004). Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Research, 64(23), 8613–8619.PubMedCrossRef
64.
Menter, D. G., Hatfield, J. S., Harkins, C., Sloane, B. F., Taylor, J. D., Crissman, J. D., et al. (1987). Tumor cell-platelet interactions in vitro and their relationship to in vivo arrest of hematogenously circulating tumor cells. Clinical and Experimental Metastasis, 5(1), 65–78.PubMedCrossRef
65.
Kopp, H. G., Placke, T., & Salih, H. R. (2009). Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Research, 69(19), 7775–7783.PubMedCrossRef
66.
Ogawa, F., Amano, H., Ito, Y., Matsui, Y., Hosono, K., Kitasato, H., et al. (2014). Aspirin reduces lung cancer metastasis to regional lymph nodes. Biomedicine and Pharmacotherapy, 68(1), 79–86.PubMedCrossRef
67.
Gautam, S., Roy, S., Ansari, M. N., Saeedan, A. S., Saraf, S. A., & Kaithwas, G. (2017). DuCLOX-2/5 inhibition: a promising target for cancer chemoprevention. Breast Cancer, 24(2), 180–190.PubMedCrossRef
68.
Hall, Z., Ament, Z., Wilson, C. H., Burkhart, D. L., Ashmore, T., Koulman, A., et al. (2016). Myc expression drives aberrant lipid metabolism in lung cancer. Cancer Research, 76(16), 4608–4618.PubMedCrossRef
69.
Knab, L. M., Grippo, P. J., & Bentrem, D. J. (2014). Involvement of eicosanoids in the pathogenesis of pancreatic cancer: the roles of cyclooxygenase-2 and 5-lipoxygenase. World Journal Gastroenterology, 20(31), 10729–10739.CrossRef
70.
71.
Dilly, A. K., Tang, K., Guo, Y., Joshi, S., Ekambaram, P., Maddipati, K. R., et al. (2017). Convergence of eicosanoid and integrin biology: role of Src in 12-LOX activation. Experimental Cell Research, 351(1), 1–10.PubMedCrossRef
72.
Dilly, A. K., Ekambaram, P., Guo, Y., Cai, Y., Tucker, S. C., Fridman, R., Kandouz, M., et al. (2013). Platelet-type 12-lipoxygenase induces MMP9 expression and cellular invasion via activation of PI3K/Akt/NF-κB. International Journal of Cancer, 133(8), 1784–1791.PubMedPubMedCentralCrossRef
73.
Nie, D., & Honn, K. V. (2002). Cyclooxygenase, lipoxygenase and tumor angiogenesis. Cellular and Mollecular Life Sciences, 59(5), 799–807.CrossRef
74.
Maskrey, B. H., Bermúdez-Fajardo, A., Morgan, A. H., Stewart-Jones, E., Dioszeghy, V., Taylor, G. W., et al. (2007). Activated platelets and monocytes generate four hydroxyphosphatidylethanolamines via lipoxygenase. Journal of Biological Chemistry, 282(28), 20151–20163.PubMedCrossRef
75.
Kandouz, M., Nie, D., Pidgeon, G. P., Krishnamoorthy, S., Maddipati, K. R., & Honn, K. V. (2003). Platelet-type 12-lipoxygenase activates NF-kappaB in prostate cancer cells. Prostaglandins and Other Lipid Mediators, 71(3–4), 189–204.PubMedCrossRef
76.
Mehta, P., Lawson, D., Ward, M. B., Lee-Ambrose, L., & Kimura, A. (1986). Effects of thromboxane A2 inhibition on osteogenic sarcoma cell-induced platelet aggregation. Cancer Reserch, 46(10), 5061–5063.
77.
Steinert, B. W., Tang, D. G., Grossi, I. M., Umbarger, L. A., & Honn, K. V. (1993). Studies on the role of platelet eicosanoid metabolism and integrin alpha IIb beta in tumor-cell-induced platelet aggregation. International Journal of Cancer, 54(1), 92–101.PubMedCrossRef
78.
Thun, M. J., Jacobs, E. J., & Patrono, C. (2012). The role of aspirin in cancer prevention. Nature Reviews. Clinical Oncology, 9(5), 259–267.PubMedCrossRef
79.
Sutcliffe, P., Connock, M., Gurung, T., Freeman, K., Johnson, S., Kandala, N. B., et al. (2013). Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews. Health Technology Assessments, 17(43), 1–253.
80.
Coppinger, J. A., O'Connor, R., Wynne, K., Flanagan, M., Sullivan, M., Maguire, P. B., et al. (2007). Moderation of the platelet releasate response by aspirin. Blood, 109(11), 4786–4792.PubMedCrossRef
81.
Zhao, L., Zhang, W., Chen, M., Zhang, J., Zhang, M., & Dai, K. (2013). Aspirin induces platelet apoptosis. Platelets, 24(8), 637–642.PubMedCrossRef
82.
Di Francesco, L., López Contreras, L. A., Sacco, A., & Patrignani, P. (2015). New insights into the mechanism of action of aspirin in the prevention of colorectal neoplasia. Current Pharmaceutical Design, 21(35), 5116–5126.PubMedCrossRef
83.
Ding, J. H., Yuan, L. Y., Huang, R. B., & Chen, G. A. (2014). Aspirin inhibits proliferation and induces apoptosis of multiple myeloma cells through regulation of Bcl-2 and Bax and suppression of VEGF. European Journal of Haematology, 93(4), 329–339.PubMedCrossRef
84.
Ding, J. H., Yuan, L. Y., & Chen, G. A. (2017). Aspirin enhances the cytotoxic activity of bortezomib against myeloma cells via suppression of Bcl-2, survivin and phosphorylation of AKT. Oncology Letters, 13(2), 647–654.PubMed
85.
Cooke, N. M., Spillane, C. D., Sheils, O., O'Leary, J., & Kenny, D. (2015). Aspirin and P2Y12 inhibition attenuate platelet-induced ovarian cancer cell invasion. BioMed Central Cancer, 15, 627–637.PubMedPubMedCentral
86.
Vad, N. M., Kudugunti, S. K., Wang, H., Bhat, G. J., & Moridani, M. Y. (2014). Efficacy of acetylsalicylic acid (aspirin) in skin B16-F0 melanoma tumor-bearing C57BL/6 mice. Tumor Biology, 35(5), 4967–4976.PubMedCrossRef
87.
Sitia, G., Iannacone, M., & Guidotti, L. G. (2013). Anti-platelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma. Journal of Hepatology, 59(5), 1135–1138.PubMedCrossRef
88.
89.
He, Y., Huang, H., Farischon, C., Li, D., Du, Z., Zhang, K., et al. (2017). Combined effects of atorvastatin and aspirin on growth and apoptosis in human prostate cancer cells. Oncology Reports, 37(2), 953–960.PubMed
90.
Aiolfi, R., & Sitia, G. (2014). Emerging role of dual antiplatelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma. Journal of Hepatocellular Carcinoma, 1, 183–186.PubMedPubMedCentral
91.
92.
Hochmuth, F., Jochem, M., & Schlattmann, P. (2016). Meta-analysis of aspirin use and risk of lung cancer shows notable results. European Journal of Cancer Prevention, 25(4), 259–268.PubMedCrossRef
93.
Medina, C., Harmon, S., Inkielewicz, I., Santos-Martinez, M. J., Jones, M., Cantwell, P., et al. (2012). Differential inhibition of tumor cell-induced platelet aggregation by the nicotinate aspirin prodrug (ST0702) and aspirin. British Journal of Pharmacology, 166(3), 938–949.PubMedPubMedCentralCrossRef
94.
Bando, H., Yamashita, T., & Tsubura, E. (1984). Effects of antiplatelet agents on pulmonary metastases. Gann, 75, 284–291.PubMed
95.
Mamytbeková, A., Rezábek, K., Kacerovská, H., Grimová, J., & Svobodová, J. (1986). Antimetastatic effect of flurbiprofen and other platelet aggregation inhibitors. Neoplasma, 33, 417–421.PubMed
96.
Mehta, P., Lawson, D., Ward, M. B., Lee-Ambrose, L., & Kimura, A. (1986). Effect of tromboxane A2 inhibition on osteogenic sarcoma cell-induced platelet aggregation. Cancer Research, 46, 5061–5063.PubMed
97.
Olson, J. D., Zaleski, A., Herrmann, D., & Flood, P. A. (1989). Adhesion of platelets to purified solid-phase von Willebrand factor: effects of wall shear rate, ADP, thrombin, and ristocetin. Journal of Laboratory and Clinical Medicine, 114(1), 6–18.PubMed
98.
Jurasz, P., Stewart, M. W., Radomski, A., Khadour, F., Duszyk, M., & Radomski, M. W. (2001). Role of von Willebrand factor in tumour cell-induced platelet aggregation: differential regulation by NO and prostacyclin. British Journal of Pharmacology, 134, 1104–1112.PubMedPubMedCentralCrossRef
99.
Stürmer, T., Glynn, R. J., Lee, I. M., Manson, J. E., Buring, J. E., & Hennekens, C. H. (1998). Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians’ Health Study. Annuals of Internal Medicine, 128(9), 713–720.CrossRef
100.
Cooper, K., Squires, H., Carroll, C., Papaioannou, D., Booth, A., Logan, R. F., Maguire, C., et al. (2010). Chemoprevention of colorectal cancer: systematic review and economic evaluation. Health Technology Assessment, 14(32), 1–206.CrossRef
101.
Rothwell, P. M., Wilson, M., Elwin, C. E., Norrving, B., Algra, A., Warlow, C. P., & Meade, T. W. (2010). Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet, 376(9754), 1741–1750.PubMedCrossRef
102.
Algra, A. M., & Rothwell, P. M. (2012). Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncology, 13(5), 518–527.PubMedCrossRef
103.
Bosettik, C., Gallus, S., & La Vecchia, C. (2009). Aspirin and cancer risk: a summary review to 2007. Recent Results in Cancer Research, 181, 231–251.CrossRef
104.
Rothwell, P. M., Price, J. F., Fowkes, F. G., Zanchetti, A., Roncaglioni, M. C., Tognoni, G., et al. (2012). Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet, 379(9826), 1602–1612.PubMedCrossRef
105.
Rothwell, P. M., Wilson, M., Price, J. F., Belch, J. F., Meade, T. W., & Mehta, Z. (2012). Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet, 379(9826), 1591–1601.PubMedCrossRef
106.
Gierach, G. L., Lacey, J. V., Schatzkin, A., Leitzmann, M. F., Richesson, D., Hollenbeck, A. R., & Brinton, L. A. (2008). Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health-AARP diet and health study. Breast Cancer Research, 10(2), R38.PubMedPubMedCentralCrossRef
107.
108.
Takkouche, B., Regueira-Mendez, C., & Etminan, M. (2008). Breast cancer and use of nonsteroidal anti-inflammatory drugs: a metaanalysis. Journal National Cancer Institute, 100(20), 1439–1447.CrossRef
109.
Dasgupta, K., Di Cesar, D., Ghosn, J., Rajan, R., Mahmud, S., & Rahme, E. (2006). Association between nonsteroidal anti-inflammatory drugs and prostate cancer occurrence. Cancer Journal, 12(2), 130–135.
110.
Habel, L. A., Zhao, W., & Stanford, J. L. (2002). Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Cancer Causes & Control, 13(5), 427–434.CrossRef
111.
Jacobs, E. J., Rodriguez, C., Mondul, A. M., Connell, C. J., Henley, S. J., Calle, E. E., & Thun, M. J. (2005). A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. Journal of National Cancer Institute, 97(13), 975–980.CrossRef
112.
Mahmud, S. M., Franco, E. L., & Aprikian, A. G. (2010). Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis. International Journal of Cancer, 127, 1680–1691.PubMedCrossRef
113.
Jacobs, C. D., Chun, S. G., Yan, J., Xie, X. J., Pistenmaa, D. A., Hannan, R., Lotan, Y., et al. (2014). Aspirin improves outcome in high risk prostate cancer patients treated with radiation therapy. Cancer Biology & Therapy, 15(6), 699–706.CrossRef
114.
Pidgeon, G. P., Lysaght, J., Krishnamoorthy, S., Reynolds, J. V., O'Byrne, K., Nie, D., & Honn, K. V. (2007). Lipoxygenase metabolism: roles in tumor progression and survival. Cancer Metastasis Review, 26(3–4), 503–524.CrossRef
115.
Rásó, E., Döme, B., Somlai, B., Zacharek, A., Hagmann, W., Honn, K. V., & Tímár, J. (2004). 12-lipoxygenase in human melanoma progression, under experimental and clinical conditions. Melanoma Research, 14(4), 245–250.PubMedCrossRef
116.
Melstrom, L. G., Bentrem, D. J., Salabat, M. R., Kennedy, T. J., Ding, X. Z., Strouch, M., et al. (2008). Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model. Clinical Cancer Research, 14(20), 6525–6530.PubMedCrossRef
117.
Ye, Y. N., Wu, W. K., Shin, V. Y., Bruce, I. C., Wong, B. C., & Cho, C. H. (2005). Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke. Carcinogenesis, 26(4), 827–834.PubMedCrossRef
118.
Lövey, J., Nie, D., Tóvári, J., Kenessey, I., Tímár, J., Kandouz, M., et al. (2013). Radiosensitivity of human prostate cancer cells can be modulated by inhibition of 12-lipoxygenase. Cancer Letters, 335(2), 495–501.PubMedCrossRef
119.
Tong, W. G., Ding, X. Z., Witt, R. C., & Adrian, T. E. (2002). Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway. Molecular Cancer Therapy, 1(11), 929–935.
120.
Pidgeon, G. P., Tang, K., Cai, Y. L., Piasentin, E., & Honn, K. V. (2003). Overexpression of platelet-type 12-lipoxygenase promotes tumor cell survival by enhancing alpha(v)beta(3) and alpha(v)beta(5) integrin expression. Cancer Research, 63(14), 4258–4267.PubMed
121.
Wang, Y., Sun, Y., Li, D., Zhang, L., Wang, K., Zuo, Y., et al. (2013). Platelet P2Y12 is involved in murine pulmonary metastasis. PloS One, 8(11), e80780.PubMedPubMedCentralCrossRef
122.
Bambace, N. M., Levis, J. E., & Holmes, C. E. (2010). The effect of P2Y-mediated platelet activation on the release of VEGF and endostatin from platelets. Platelets, 21(2), 85–93.PubMedCrossRef
123.
Schumacher, D., Strilic, B., Sivaraj, K. K., Wettschureck, N., & Offermanns, S. (2013). Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer Cell, 24(1), 130–137.PubMedCrossRef
124.
Gebremeskel, S., LeVatte, T., Liwski, R. S., Johnston, B., & Bezuhly, M. (2015). The reversible P2Y12 inhibitor ticagrelor inhibits metastasis and improves survival in mouse models of cancer. International Journal of Cancer, 136(1), 234–240.PubMedCrossRef
125.
Bastida, E., Escolar, G., Almirall, L., & Ordinas, A. (1986). Platelet activation induced by a human neuroblastoma tumor cell line is reduced by prior administration of ticlopidine. Thrombosis and Haemostasis, 55(3), 333–337.PubMed
126.
Mah-Becherel, M. C., Céraline, J., Deplanque, G., Chenard, M. P., Bergerat, J. P., Cazenave, J. P., & Klein-Soyer, C. (2002). Anti-angiogenic effects of the thienopyridine SR 25989 in vitro and in vivo in a murine pulmonary metastasis model. British Journal of Cancer, 86(5), 803–810.PubMedPubMedCentralCrossRef
127.
Kohga, S., Kinjo, M., Tanaka, K., Ogawa, H., Ishihara, M., & Tanaka, N. (1981). Effects of 5-(2-chlorobenzyl)-4,5,6,7,-tetrahydrothieno[3,2-C]pyridine hydrochloride (ticlopidine), a platelet aggregation inhibitor, on blood-borne metastasis. Cancer Research, 41, 4710–4714.PubMed
128.
Fabra, A., de Castellarnau, C., Carretero, F., Martinez, E., Sancho, M. J., & Rutllant, M. L. (1987). Effects of ticlopidine on metastasis production in mice bearing Lewis lung carcinoma. Invasion & Metastasis, 7, 53–60.
129.
Mezouar, S., Darbousset, R., Dignat-George, F., Panicot-Dubois, L., & Dubois, C. (2015). Inhibition of platelet activation prevents the P-selectin and integrin-dependent accumulation of cancer cell microparticles and reduces tumor growth and metastasis in vivo. International Journal of Cancer, 136(2), 462–475.PubMedCrossRef
130.
Geddings, J. E., Hisada, Y., Boulaftali, Y., Getz, T. M., Whelihan, M., Fuentes, R., et al. (2016). Tissue factor-positive tumor microvesicles activate platelets and enhance thrombosis in mice. Journal of Thrombosis and Haemostasis, 14(1), 153–166.PubMedCrossRef
131.
Roop, R. P., Naughton, M. J., Van Poznak, C., Schneider, J. G., Lammers, P. E., Pluard, T. J., et al. (2013). A randomized phase II trial investigating the effect of platelet function inhibition on circulating tumor cells in patients with metastatic breast cancer. Clinical Breast Cancer, 13(6), 409–415.PubMedPubMedCentralCrossRef
132.
Serebruany, V. L. (2015). Ticagrelor shift from PLATO to PEGASUS: vanished mortality benefit, excess cancer deaths, massive discontinuations, and overshooting target events. International Journal of Cardiology, 201, 508–512.PubMedCrossRef
133.
Li, X., Fries, S., Li, R., Lawson, J. A., Propert, K. J., Diamond, S. L., et al. (2014). Differential impairment of aspirin-dependent platelet cyclooxygenase acetylation by nonsteroidal antiinflammatory drugs. Proceedings of the National Academy of Sciences, 111(47), 16830–16835.CrossRef
134.
Jin, J., Quinton, T. M., Zhang, J., Rittenhouse, S. E., & Kunapuli, S. P. (2002). Adenosine diphosphate (ADP)-induced thromboxane a(2) generation in human platelets requires coordinated signaling through integrin alpha(IIb)beta(3) and ADP receptors. Blood, 99(1), 193–198.PubMedCrossRef
135.
Wei, C. K., Chang, F. R., Hsieh, P. W., & Wu, C. C. (2015). Inhibition of the interactions between metastatic human breast cancer cells and platelets by β-nitrostyrene derivatives. Life Sciences, 143, 147–155.PubMedCrossRef
136.
Uluçkan, O., Eagleton, M. C., Floyd, D. H., Morgan, E. A., Hirbe, A. C., Kramer, M., et al. (2008). APT102, a novel adpase, cooperates with aspirin to disrupt bone metastasis in mice. Journal of Cellular Biochemistry, 104(4), 1311–1323.PubMedPubMedCentralCrossRef
137.
Giordano, A., Musumeci, G., D'Angelillo, A., Rossini, R., Zoccai, G. B., Messina, S., et al. (2016). Effects of glycoprotein IIb/IIIa antagonists: anti-platelet aggregation and beyond. Current Drug Metabolism, 17(2), 194–203.PubMedCrossRef
138.
Dardik, R., Savion, N., Kaufmann, Y., & Varon, D. (1998). Thrombin promotes platelet-mediated melanoma cell adhesion to endothelial cells under flow conditions: role of platelet glycoproteins P-selectin and GPIIb-IIIA. British Journal of Cancer, 77(12), 2069–2075.PubMedPubMedCentralCrossRef
139.
Yu, Y., Zhou, X. D., Liu, Y. K., Ren, N., Chen, J., & Zhao, Y. J. (2002). Platelets promote the adhesion of human hepatoma cells with a highly metastatic potential to extracellular matrix protein: involvement of platelet P-selectin and GP IIb-IIIa. Journal Cancer Research and Clinical Oncology, 128(5), 283–287.PubMedCrossRef
140.
Stouffer, G. A., & Smyth, S. S. (2003). Effects of thrombin on interactions between beta3-integrins and extracellular matrix in platelets and vascular cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 23(11), 1971–1978.PubMedCrossRef
141.
Grossi, I. M., Fitzgerald, L. A., Kendall, A., Taylor, J. D., Sloane, B. F., & Honn, K. V. (1987). Inhibition of human tumor cell induced platelet aggregation by antibodies to platelet glycoproteins Ib and IIb/IIIa. Proceedings of the Society for Experimental Biology and Medicine, 186(3), 378–383.PubMedCrossRef
142.
Karpatkin, S., Pearlstein, E., Ambrogio, C., & Coller, B. S. (1988). Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. Journal of Clinical Investigation, 81(4), 1012–1019.PubMedPubMedCentralCrossRef
143.
Coller, B. S. (2001). Anti-GpIIb/IIIa drugs: current strategies and future directions. Thrombosis and Haemostasis, 86, 427–443.PubMed
144.
Huang, F., & Hong, E. (2004). Platelet glycoprotein IIb/IIIa inhibition and its clinical use. Cardiovascular & Hematological Agents in Medicinal Chemistry, 2(3), 187–196.CrossRef
145.
Kononczuk, J., Surazynski, A., Czyzewska, U., Prokop, I., Tomczyk, M., Palka, J., & Miltyk, W. (2015). αIIbβ3-integrin ligands: abciximab and eptifibatide as proapoptotic factors in MCF-7 human breast cancer cells. Current Drug Targets, 16(13), 1429–1437.PubMedCrossRef
146.
Hagemeyer, C. E., & Peter, K. (2010). Targeting the platelet integrin GPIIb/IIIa. Current Pharmaceutical Design, 16(37), 4119–4133.PubMedCrossRef
147.
Sheu, J. R., Lin, C. H., Peng, H. C., Teng, C. M., & Huang, T. F. (1993). Triflavin, an Arg-Gly-Asp-containing peptide, inhibits tumor cell-induced platelet aggregation. Japanese Journal of Cancer Research, 84(10), 1062–1071.PubMedCrossRef
148.
Lonsdorf, A. S., Krämer, B. F., Fahrleitner, M., Schönberger, T., Gnerlich, S., Ring, S., et al. (2012). Engagement of αIIbβ3 (GPIIb/IIIa) with ανβ3 integrin mediates interaction of melanoma cells with platelets: a connection to hematogenous metastasis. The Journal of Biological Chemistry, 287(3), 2168–2178.PubMedCrossRef
149.
Nierodzik, M. L., Klepfish, A., & Karpatkin, S. (1995). Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo. Thrombosis and Haemostasis, 74, 282–290.PubMed
150.
Amirkhosravi, A., Amaya, M., Siddiqui, F., Biggerstaff, J. P., Meyer, T. V., & Francis, J. L. (1990). Blockade of GpIIb/IIIa inhibits the release of vascular endothelial growth factor (VEGF) from tumor-cell-activated platelets and experimental metastasis. Platelets, 10, 285–292.CrossRef
151.
Chiang, H. S., Swaim, M. W., & Huang, T. F. (1994). Characterization of platelet aggregation induced by human colon adenocarcinoma cells and its inhibition by snake venom peptides, trigramin and rhodostomin. British Journal of Haematology, 87, 325–331.PubMedCrossRef
152.
Chiang, H. S., Swaim, M. W., & Huang, T. F. (1995). The Arg-Gly-Asp-containing peptide, rhodostomin, inhibits in vitro cell adhesion to extracellular matrices and platelet aggregation caused by saos-2 human osteosarcoma cells. British Journal of Cancer, 71, 265–270.PubMedPubMedCentralCrossRef
153.
Swaim, M. W., Chiang, H. S., & Huang, T. F. (1996). Characterisation of platelet aggregation induced by PC-3 human prostate adenocarcinoma cells and inhibited by venom peptides, trigramin and rhodostomin. European Journal of Cancer, 32A(4), 715–721.PubMedCrossRef
154.
Bakewell, S. J., Nestor, P., Prasad, S., Tomasson, M. H., Dowland, N., Mehrotra, M., et al. (2003). Platelet and osteoclast beta3 integrins are critical for bone metastasis. Proceedings of the National Academy of Sciences of the United States of America, 100(24), 14205–14210.PubMedPubMedCentralCrossRef
155.
Schneider, J. G., Amend, S. R., & Weilbaecher, K. N. (2011). Integrins and bone metastasis: integrating tumor cell and stromal cell interactions. Bone, 48(1), 54–65.PubMedCrossRef
156.
Esposito, M., & Kang, Y. (2014). Targeting tumor-stromal interactions in bone metastasis. Pharmacology Therapy, 141(2), 222–233.CrossRef
157.
Zhang, W., Dang, S., Hong, T., Tang, J., Fan, J., Bu, D., et al. (2012). A humanized single-chain antibody against beta 3 integrin inhibits pulmonary metastasis by preferentially fragmenting activated platelets in the tumor microenvironment. Blood, 120(14), 2889–2898.PubMedPubMedCentralCrossRef
158.
Amirkhosravi, A., Mousam, S. A., Amaya, M., Blaydes, S., Desai, H., Meyer, T., & Francis, J. L. (2003). Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb/IIIa antagonist XV454.Thrombosis and. Haemostasis, 90(3), 549–554.
159.
Trikha, M., Zhou, Z., Jordan, J., & Nakada, M. T. (2000). ReoPro and m7E3 F(ab’)2 inhibit β3 integrin mediated tumor growh and angiogenesis. Proceedings of the American Association for Cancer Research, 42, 824 [Abstract].
160.
Huang, Z., Miao, X., Patarroyo, M., Nilsson, G. P., Pernow, J., & Li, N. (2016). Tetraspanin CD151 and integrin α6β1 mediate platelet-enhanced endothelial colony forming cell angiogenesis. Thrombosis and Haemostasis, 14(3), 606–618.CrossRef
161.
Zhu, G., Zhang, Q., Reddy, E.C., Carrim, N., Chen, Y., Xu, X.R., et al. (2017). Integrin PSI domain has endogenous thiol isomerase function and is a novel target for anti-platelet therapy. Blood, 2017 Jan 25. doi: 10.​1182/​blood-2016-07-729400.
162.
Qian, W., Tao, L., Wang, Y., Zhang, F., Li, M., Huang, S., et al. (2015). Downregulation of Integrins in cancer cells and anti-platelet properties are involved in holothurian glycosaminoglycan-mediated disruption of the interaction of cancer cells and platelets in Hematogenous metastasis. Journal of Vascular Research, 52(3), 197–209.PubMedCrossRef
163.
Hall, C. L., Dubyk, C. W., Riesenberger, T. A., Shein, D., Keller, E. T., & van Golen, K. L. (2008). Type I collagen receptor (alpha2beta1) signaling promotes prostate cancer invasion through RhoC GTPase. Neoplasia, 10(8), 797–803.PubMedPubMedCentralCrossRef
164.
Eke, I., Zscheppang, K., Dickreuter, E., Hickmann, L., Mazzeo, E., Unger, K., et al. (2015). Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer. Journal of the National Cancer Institute, 107(2). doi:10.​1093/​jnci/​dju419.
165.
Erpenbeck, L., & Schön, M. P. (2010). Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. Blood, 115(17), 3427–3436.PubMedPubMedCentralCrossRef
166.
Bambace, N. M., & Holmes, C. E. (2011). The platelet contribution to cancer progression. Journal Thrombosis and Haemostasis, 9(2), 237–249.CrossRef
167.
Jain, S., Russell, S., & Ware, J. (2009). Platelet glycoprotein VI facilitates experimental lung metastasis in syngenic mouse models. Journal Thrombosis and Haemostasis, 7(10), 1713–1717.CrossRef
168.
Jain, S., Zuka, M., Liu, J., Russell, S., Dent, J., Guerrero, J. A., et al. (2007). Platelet glycoprotein Ib alpha supports experimental lung metastasis. Proceedings of the National Academy of Sciences, 104(21), 9024–9028.CrossRef
169.
Nieswandt, B., & Watson, S. P. (2003). Platelet-collagen interaction: is GPVI the central receptor? Blood, 102, 449–461.PubMedCrossRef
170.
Erpenbeck, L., Nieswandt, B., Schön, M., Pozgajova, M., & Schön, M. P. Inhibition of platelet GPIbalpha and promotion of melanoma metastasis. Journal of Investigative Dermatology, 130(2), 576–586.
171.
172.
Stevenson, J. L., Varki, A., & Borsig, L. (2007). Heparin attenuates metastasis mainly due to inhibition of P- and L-selectin, but non-anticoagulant heparins can have additional effects. Thrombosis Research, 120(suppl2), S107–S111.PubMedCrossRef
173.
Borsig, L., Wong, R., Feramisco, J., Nadeau, D. R., Varki, N. M., & Varki, A. (2001). Heparin and cancer revised: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. PNAS, 98, 3352–3357.PubMedPubMedCentralCrossRef
174.
Ludwig, R. J., Beohme, B., Podda, M., Henschler, R., Jager, E., Tandi, C., et al. (2004). Endothelial P-selectin as a target of heparinb action in experimental melanoma lung metastasis. Cancer Research, 64, 2743–2750.PubMedCrossRef
175.
Kozlowski, E. O., Pavao, M. S., & Borsig, L. (2011). Ascidian dermatan sulfates attenuate metastasis, inflammation and thrombosis by inhibition of P-selectin. Journal Thrombosis and Haemostasis, 9(9), 1807–1815.CrossRef
176.
Di Vito, C., Navone, S. E., Marfia, G., Abdel Hadi, L., Mancuso, M. E., Pecci, A., et al. (2016). Platelets from glioblastoma patients promote angiogenesis of tumor endothelial cells and exhibit increased VEGF content and release. Platelets, 29, 1–10. doi:10.​1080/​09537104.​2016.​1247208.CrossRef
177.
Nylander, S., Mattsson, C., Ramström, S., & Lindahl, T. L. (2003). The relative importance of the ADP receptors, P2Y12 and P2Y1, in thrombin-induced platelet activation. Thrombosis Research, 111(1–2), 65–73.PubMedCrossRef
178.
Wojtukiewicz, M.Z., Ciarelli, J.J., Walz, D.A., Honn, K.V. (1990). Thrombin enhances cancer cell expression of an integrin receptor and increases adhesion. 81st Annual Meeting of the Americsan Association for Cancer Research, Washington, Proceedings of AACR, 31, Abstract 476.
179.
Wojtukiewicz, M.Z., Ciarelli, J.J., Snyder, D.A., Nelson, K.K., Walz, D.A., Honn, K.V.. (1990). Increased tumor cell adhesiveness and experimental metastasis following exposure to alpha-thrombin, its precursor and analogues. American Cancer Society Michigan Division Inc., 1990 Cancer Research Conference, Ypsilanti, MI, USA, Poster 22.
180.
Wojtukiewicz, M.Z., Ciarelli, J.J., Snyder, D., Nelson, K.K., Walz, D.A., Honn, K.V. (1990). Thrombin increases tumor cell adhesiveness via a non-proteolytic pathway. First Regional Meeting of the American Society for Cell Biology, Chicago, IL, USA, 1990, Abstract 91.
181.
Wojtukiewicz, M. Z., Tang, D. G., Nelson, K. K., Walz, D. A., Diglio, C. A., & Honn, K. V. (1992). Thrombin enhances tumor cell adhesive and metastatic properties via increased alpha IIb beta 3 expression on the cell surface. Thrombosis Research, 68, 233–245.PubMedCrossRef
182.
Wojtukiewicz, M. Z., Tang, D. G., Ciarelli, J. J., Nelson, K. K., Walz, D. A., Diglio, C. A., et al. (1993). Thrombin increases the metastatic potential of tumor cells. International Journal of Cancer, 54, 793–806.PubMedCrossRef
183.
Nierodzik, M. L., Kajumo, F., & Karpatkin, S. (1992). Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo. Cancer Research, 52(12), 3267–3272.PubMed
184.
Nierodzik, M., Plotkin, A., Kajumo, F., & Karpatkin, S. (1991). Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo. Journal of Clinical Investigation, 87(1), 229–236.PubMedPubMedCentralCrossRef
185.
Yuan, L., & Liu, X. (2015). Platelets are associated with xenograft tumor growth and the clinical malignancy of ovarian cancer through an angiogenesis-dependent mechanism. Molecular Medicine Reports, 11(4), 2449–2458.PubMed
186.
Pearlstein, E., Ambrogio, C., Gasic, G., Karpatkin, S., et al. (1982). Inhibition of the platelet-aggregating activity of two human adenocarcinomas of the colon and an anaplastic murine tumor with a specific thrombin inhibitor: dansylarginine N-(3-ethyl-1, 5-pentanediyl)amide. Progress in Clinical and Biological Research, 89, 479–502.PubMed
187.
Nieman, M. T., LaRusch, G., Fang, C., Zhou, Y., & Schmaier, A. H. (2010). Oral thrombostatin FM19 inhibits prostate cancer. Thrombosis and Haemostasis, 104(5), 1044–1048.PubMedPubMedCentralCrossRef
188.
Lu, Q., Lv, M., Xu, E., Shao, F., Feng, Y., Yang, J., & Shi, L. (2015). Recombinant hirudin suppresses the viability, adhesion, migration and invasion of Hep-2 human laryngeal cancer cells. Oncology Reports, 33(3), 1358–1364.PubMed
189.
Guo, R. R., Liu, Y., Lu, W. L., Zhao, J. H., Wang, X. Q., Zhang, H., et al. (2008). A recombinant peptide, hirudin, potentiates the inhibitory effects of stealthy liposomal vinblastine on the growth and metastasis of melanoma. Biological and Pharmacological Bulletin, 31(4), 696–702.CrossRef
190.
Sassi, M., Chakroun, T., Mbemba, E., Van Dreden, P., Elalamy, I., Larsen, A. K., & Gerotziafas, G. T. (2017). The antithrombotic potential of tinzaparin and enoxaparin upon thrombin generation triggered in vitro by human ovarian cancer cells IGROV1. Clinical and Applied Thrombosis/Hemostasis, 23(2), 155–163.PubMedCrossRef
191.
Niers, T. M., Klerk, C. P., DiNisio, M., Van Noorden, C. J., Büller, H. R., Reitsma, P. H., & Richel, D. J. (2007). Mechanisms of heparin induced anti-cancer activity in experimental cancer models. Critical Reviews in Oncology and Hematology, 61(3), 195–207.CrossRef
192.
Laubli, H., & Borsig, L. (2009). Heparins attenuate cancer metastasis: are selectins the link? Cancer Investment, 27(5), 474–481.CrossRef
193.
Borsig, L. (2007). Antimetastatic activities of modified heparins: selectin inhibition by heparin attenuates metastasis. Seminars in Thrombosis and Hemostasis, 33(5), 540–546.PubMedCrossRef
194.
Varki, N. M., & Varki, A. (2002). Heparin inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans. Seminars in Thrombosis and Hemostasis, 28(1), 53–66.PubMedCrossRef
195.
Stevenson, J. L., Choi, S. H., & Varki, A. (2005). Differential metastasis inhibition by clinically relevant levels of heparins: correlation with selectin inhibition, not antithrombotic activity. Clinical Cancer Research, 11(19), 7003–7011.PubMedCrossRef
196.
Gomes, A. M., Kozlowski, E. O., Borsig, L., Teixeira, F. C., Vlodavsky, I., & Pavão, M. S. (2015). Antitumor properties of a new non-anticoagulant heparin analog from the mollusc Nodipecten nodosus: effect on P-selectin, heparanase, metastasis and cellular recruitment. Glycobiology, 25(4), 386–393.PubMedCrossRef
197.
Battinelli, E. M., Markens, B. A., Kulenthirarajan, R. A., Machlus, K. R., Flaumenhaft, R., & Italiano, J. E. (2014). Anticoagulation inhibits tumor cell-mediated release of platelet angiogenic proteins and diminishes platelet angiogenic response. Blood, 123(1), 101–112.PubMedPubMedCentralCrossRef
198.
Goertz, L., Schneider, S. W., Desch, A., Mayer, F. T., Koett, J., Nowak, K., et al. (2016). Heparins that block VEGF-A-mediated von Willebrand factor fiber generation are potent inhibitors of hematogenous but not lymphatic metastasis. Oncotarget, 7(42), 68527–68545.PubMedPubMedCentralCrossRef
199.
200.
Asanuma, K., Wakabayashi, H., Okamoto, T., Asanuma, Y., Akita, N., Yoshikawa, T., et al. (2013). The thrombin inhibitor, argatroban, inhibits breast cancer metastasis to bone. Breast Cancer, 20(3), 241–246.PubMedCrossRef
201.
Asanuma, K., Wakabayashi, H., Hayashi, T., Okuyama, N., Seto, M., Matsumine, A., Kusuzaki, K., et al. (2004). Thrombin inhibitor, argatroban, prevents tumor cell migration and bone metastasis. Oncology, 67(2), 166–173.PubMedCrossRef
202.
DeFeo, K., Hayes, C., Chernick, M., Ryn, J. V., & Gilmour, S. K. (2010). Use of dabigatran etexilate to reduce breast cancer progression. Cancer Biology and Therapy, 10, 1001–1008.PubMedCrossRef
203.
Alexander, E. T., Minton, A. R., Hayes, C. S., Goss, A., Van Ryn, J., Gilmour, S. K., et al. (2015). Thrombin inhibition and cyclophosphamide synergistically block tumor progression and metastasis. Cancer Biology & Therapy, 16(12), 1802–1811. doi:10.​1080/​15384047.​2015.​1078025.CrossRef
204.
Alexander, E. T., Minton, A. R., Peters, M. C., van Ryn, J., & Gilmour, S. K. (2016). Thrombin inhibition and cisplatin block tumor progression in ovarian cancer by alleviating the immunosuppressive microenvironment. Oncotarget, 7(51), 85291–85305.PubMedPubMedCentral
205.
Shi, K., Damhofer, H., Daalhuisen, J., Ten Brink, M., Richel, D. J., & Spek, C. A. (2017). Dabigatran potentiates gemcitabine-induced growth inhibition of pancreatic cancer in mice. Molecular Medicine, 6, 23. doi:10.​2119/​molmed.​2016.​00214.
206.
Vianello, F., Sambado, L., Goss, A., Fabris, F., & Prandoni, P. (2016). Dabigatran antagonizes growth, cell-cycle progression, migration, and endothelial tube formation induced by thrombin in breast and glioblastoma cell lines. Cancer Medicine, 5(10), 2886–2898.PubMedPubMedCentralCrossRef
207.
Rousseau, A., Van Dreden, P., Mbemba, E., Elalamy, I., Larsen, A., & Gerotziafas, G. T. (2015). Cancer cells BXPC3 and MCF7 differentially reverse the inhibition of thrombin generation by apixaban, fondaparinux and enoxaparin. Thrombosis Research, 136(6), 1273–1279.PubMedCrossRef
208.
Kirwan, C. C., Bundred, N. J., Castle, J., Clarke, R., Dive, C., Morris, J., et al. (2016). PO-36 thrombin inhibition preoperatively (TIP) in early breast cancer, the first clinical trial of NOACs as an anti-cancer agent: trial methodology. Thrombosis Research, 140(Suppl 1), S189–S190. doi:10.​1016/​S0049-3848(16)30169-4.PubMedCrossRef
209.
Zhang, P., Feng, S., Liu, G., Wang, H., Zhu, H., Ren, Q., et al. (2016). Mutant B-Raf (V600E) promotes melanoma paracellular transmigration by inducing thrombin-mediated endothelial junction breakdown. Journal of Biological Chemistry, 291(5), 2087–2106.PubMedCrossRef
210.
Kakkar AK. Low molecular weight heparin and survival in cancer. (2005). Haematological Report, 1: 27.
211.
Camerer, E., Qazi, A. A., Duong, D., Cornelissen, I., Advincula, R., & Coughlin, S. R. (2004). Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood, 104(2), 397–401.PubMedCrossRef
212.
Etulain, J., Mena, H. A., Negrotto, S., & Schattner, M. (2015). Stimulation of PAR-1 or PAR-4 promotes similar pattern of VEGF and endostatin release and pro-angiogenic responses mediated by human platelets. Platelets, 26(8), 799–804.PubMedCrossRef
213.
Huang, Z., Miao, X., Luan, Y., Zhu, L., Kong, F., Lu, Q., et al. (2015). PAR1-stimulated platelet releasate promotes angiogenic activities of endothelial progenitor cells more potently than PAR4-stimulated platelet releasate. Journal of Thrombosis and Haemostasis, 13(3), 465–476.PubMedCrossRef
214.
Holinstat, M., Boutaud, O., Apopa, P. L., Vesci, J., Bala, M., Oates, J. A., et al. (2011). Protease-activated receptor signaling in platelets activates cytosolic phospholipase A2α differently for cyclooxygenase-1 and 12-lipoxygenase catalysis. Arteriosclerosis, Thrombosis, Vascular, and Biology, 31(2), 435–442.CrossRef
215.
Thomas, C. P., Morgan, L. T., Maskrey, B. H., Murphy, R. C., Kühn, H., Hazen, S. L., et al. (2010). Phospholipid-esterified eicosanoids are generated in agonist-activated human platelets and enhance tissue factor-dependent thrombin generation. The Journal of Biological Chemistry, 285(10), 6891–6903.PubMedPubMedCentralCrossRef
216.
Trivedi, V., Boire, A., Tchernychev, B., Kaneider, N. C., Leger, A. J., O'Callaghan, K., et al. (2009). Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site. Cell, 137(2), 332–343.PubMedPubMedCentralCrossRef
217.
Melnikova, V. O., Balasubramanian, K., Villares, G. J., Dobroff, A. S., Zigler, M., Wang, H., et al. (2009). Crosstalk between protease-activated receptor 1 and platelet-activating factor receptor regulates melanomacell adhesion molecule (MCAM/MUC18) expression and melanoma metastasis. Journal of Biological Chemistry, 284(42), 28845–28855.PubMedPubMedCentralCrossRef
218.
Hackler, P. C., Reuss, S., Konger, R. L., Travers, J. B., & Sahu, R. P. (2014). Systemic platelet-activating factor receptor activation augments experimental lung tumor growth and metastasis. Cancer Growth Metastasis, 7, 27–32.PubMedPubMedCentral
219.
Ferracini, M., Sahu, R. P., Harrison, K. A., Waeiss, R. A., Murphy, R. C., Jancar, S., et al. (2015). Topical photodynamic therapy induces systemic immunosuppression via generation of platelet-activating factor receptor ligands. Journal of Investigative Dermatology, 135(1), 321–323.PubMedCrossRef
220.
Sahu, R. P., Kozman, A. A., Yao, Y., DaSilva, S. C., Rezania, S., Martel, K. C., et al. (2012). Loss of the platelet activating factor receptor in mice augments PMA-induced inflammation and cutaneous chemical carcinogenesis. Carcinogenesis, 33(3), 694–701.PubMedPubMedCentralCrossRef
221.
Bihl, J. C., Rapp, C. M., Chen, Y., & Travers, J. B. (2016). UVB generates microvesicle particle release in part due to platelet-activating factor signaling. Photochemistry and Photobiology, 92(3), 503–506.PubMedPubMedCentralCrossRef
222.
Sahu, R. P., Rezania, S., Ocana, J. A., DaSilva-Arnold, S. C., Bradish, J. R., Richey, J. D., et al. (2014). Topical application of a platelet activating factor receptor agonist suppresses phorbol ester-induced acute and chronic inflammation and has cancer chemopreventive activity in mouse skin. PloS One, 9(11), e111608.PubMedPubMedCentralCrossRef
223.
Domiano, B. P., Derian, C. K., Maryanoff, B. E., Zhang, H. C., & Gordon, P. A. (2003). RWJ-58259: a selective antagonists of protease activated receptor-1. Cardiovascular Drug Review, 21, 313–326.CrossRef
224.
Hosokawa, K., Ohnishi, T., Miura, N., Sameshima, H., Koide, T., Tanaka, K. A., Maruyama, I., et al. (2014). Antithrombotic effects of PAR1 and PAR4 antagonists evaluated under flow and static conditions. Thrombosis Research, 133(1), 66–72.PubMedCrossRef
225.
Zania, P., Kritikou, S., Flordellis, C. S., Maragoudakis, T., & N.E. (2006). Blockage of angiogenesis by small molecule antagonists to protease-activated receptor-1: association with endothelial cell growth suppression and induction of apoptosis. Journal of Pharmacology and Experimental Therapeutics, 318, 246–254.PubMedCrossRef
226.
Villares, G. J., Zigler, M., Wang, H., Melnikova, V. O., Wu, H., Friedman, R., et al. (2008). Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Research, 68, 9078–9086.PubMedPubMedCentralCrossRef
227.
French, S. L., Arthur, J. F., Lee, H., Nesbitt, W. S., Andrews, R. K., Gardiner, E. E., & Hamilton, J. R. (2016). Inhibition of protease-activated receptor 4 impairs platelet procoagulant activity during thrombus formation in human blood. Journal of Thrombosis and Haemostasis, 14(8), 1642–1654.PubMedCrossRef
228.
Cunningham, M., McIntosh, K., Bushell, T., Sloan, G., & Plevin, R. (2016). Proteinase-activated receptors (PARs) as targets for antiplatelet therapy. Biochemical Society Transations, 44(2), 606–612.CrossRef
229.
Ottaiano, T. F., Andrade, S. S., de Oliveira, C., Silva, M. C., Buri, M. V., Juliano, M. A., et al. (2017). Plasma kallikrein enhances platelet aggregation response by subthreshold doses of ADP. Biochimie, 135, 72–81.PubMedCrossRef
230.
Shirai, T., Inoue, O., Tamura, S., Tsukiji, N., Sasaki, T., Endo, H., et al. (2017). C-type lectin-like receptor 2 promotes hematogenous tumor metastasis and prothrombotic state in tumor-bearing mice. Journal of Thrombosis and Haemostasis, 15(3), 513–525.PubMedCrossRef
231.
Kato, Y., Kaneko, M. K., Kunita, A., Ito, H., Kameyama, A., Ogasawara, S., Matsuura, N., et al. (2008). Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Cancer Science, 99(1), 54–61.PubMed
232.
Suzuki-Inoue, K. (2011). Essential in vivo roles of the platelet activation receptor CLEC-2 in tumor metastasis, lymphangiogenesis and thrombus formation. Journal of Biochemistry, 150(2), 127–132.PubMedCrossRef
233.
Chang, Y. W., Hsieh, P. W., Chang, Y. T., Lu, M. H., Huang, T. F., Chong, K. Y., et al. (2015). Identification of a novel platelet antagonist that binds to CLEC-2 and suppresses podoplanin-induced platelet aggregation and cancer metastasis. Oncotarget, 6(40), 42733–42748.PubMedPubMedCentralCrossRef
234.
Riedl, J., Preusser, M., Nazari, P. M., Posch, F., Panzer, S., Marosi, C., et al. (2017). Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism. Blood. doi:10.​1182/​blood-2016-06-720714.
235.
Lourbakos, A., Yuan, Y. P., Jenkins, A. L., Travis, J., Andrade-Gordon, P., Santulli, R., & Potempa, J. (2001). Activation of protease-activated receptors by gingipains from Porphyromonas gingivalis leads to platelet aggregation: a new trait in microbial pathogenicity. Blood, 97(12), 3790–3797.PubMedCrossRef
236.
Kida, Y., Higashimoto, Y., Inoue, H., Shimizu, T., & Kuwano, K. (2008). A novel secreted protease from Pseudomonas Aeruginosa activates NF-kappaB through protease-activated receptors. Cellular Microbiology, 10, 1491–1504.PubMedCrossRef
237.
Dulon, S., Leduc, D., Cottrell, G. S., D'Alayer, J., Hansen, K. K., Bunnett, N. W., & Hollenberg, M. D. (2005). Pseudomonas Aeruginosa elastase disables proteinase-activated receptor 2 in respiratory epithelial cells. American Journal of Respiratory Cell and Molecular Biology, 32, 411–419.PubMedCrossRef
238.
Majumdar, S., Dutta, S., Das, T., Chattopadhyay, P., & Mukherjee, A. K. (2015). Antiplatelet and antithrombotic activity of a fibrin(ogen)olytic protease from Bacillus Cereus strain FF01. International Journal of Biological Macromolecules, 79, 477–489.PubMedCrossRef
239.
D'Asti, E., Chennakrishnaiah, S., Lee, T. H., & Rak, J. (2016). Extracellular vesicles in brain tumor progression. Cellular and Molecular Neurobiology, 36(3), 383–407.PubMedCrossRef
240.
Wurdinger, T., Deumelandt, K., van der Vliet, H. J., Wesseling, P., & de Gruijl, T. D. (2014). Mechanisms of intimate and long-distance cross-talk between glioma and myeloid cells: how to break a vicious cycle. Biochimica et Biophysica Acta, 1846(2), 560–575.PubMed
241.
Laffont, B., Corduan, A., Plé, H., Duchez, A. C., Cloutier, N., Boilard, E., & Provost, P. (2013). Activated platelets can deliver mRNA regulatory Ago2•microRNA complexes to endothelial cells via microparticles. Blood, 122(2), 253–261.PubMedCrossRef
242.
Sadej, R., Grudowska, A., Turczyk, L., Kordek, R., & Romanska, H. M. (2014). CD151 in cancer progression and metastasis: a complex scenario. Laboratory Investigation, 94(1), 41–51.PubMedCrossRef
243.
Perrone, D., Ardito, F., Giannatempo, G., Dioguardi, M., Troiano, G., Lo Russo, L., et al. (2015). Biological and therapeutic activities, and anticancer properties of curcumin. Experimental and Therapeutic Medicine, 10(5), 1615–1623.PubMedPubMedCentral
244.
Deng, Y. I., Verron, E., & Rohanizadeh, R. (2016). Molecular mechanisms of anti-metastatic activity of curcumin. Anticancer Research, 36(11), 5639–5647.PubMedCrossRef
245.
Lu, W. J., Chang, N. C., Jayakumar, T., Liao, J. C., Lin, M. J., Wang, S. H., et al. (2014). Ex vivo and in vivo studies of CME-1, a novel polysaccharide purified from the mycelia of Cordyceps sinensis that inhibits human platelet activation by activating adenylate cyclase/cyclic AMP. Thrombosis Research, 134(6), 1301–1310.PubMedCrossRef
246.
Chang, Y., Hsu, W. H., Lu, W. J., Jayakumar, T., Liao, J. C., Lin, M. J., et al. (2015). Inhibitory mechanisms of CME-1, a novel polysaccharide from the mycelia of Cordyceps sinensis, in platelet activation. Current Pharmaceutical Biotechnology, 16(5), 451–461.PubMedCrossRef
247.
Jayakumar, T., Chiu, C. C., Wang, S. H., Chou, D. S., Huang, Y. K., & Sheu, J. R. (2014). Anti-cancer effects of CME-1, a novel polysaccharide, purified from the mycelia of Cordyceps sinensis against B16-F10 melanoma cells. Journal of Cancer Research Therapy, 10(1), 43–49.CrossRef
248.
Lin, K. H., Kuo, J. R., Lu, W. J., Chung, C. L., Chou, D. S., Huang, S. Y., Lee, H. C., et al. (2013). Hinokitiol inhibits platelet activation ex vivo and thrombus formation in vivo. Biochemical Pharmacology, 85(10), 1478–1485.PubMedCrossRef
249.
Lu, W. J., Wu, M. P., Lin, K. H., Lin, Y. C., Chou, H. C., & Sheu, J. R. (2014). Hinokitiol is a novel glycoprotein VI antagonist on human platelets. Platelets, 25(8), 595–602.PubMedCrossRef
250.
Chen, X., Li, Q., Kan, X. X., Wang, Y. J., Li, Y. J., Yang, Q., et al. (2016). Extract of Caulis Spatholobi, a novel blocker targeting tumor cell induced platelet aggregation, inhibits breast cancer metastasis. Oncology Reports, 36(6), 3215–3224.PubMed
251.
Sabrkhany, S., Griffioen, A. W., Pineda, S., Sanders, L., Mattheij, N., van Geffen, J. P., Aarts, M. J., et al. (2016). Sunitinib uptake inhibits platelet function in cancer patients. European Journal of Cancer, 66, 47–54.PubMedCrossRef
252.
Alonso-Escolano, D., Medina, C., Cieslik, K., Radomski, A., Jurasz, P., Santos-Martínez, M. J., et al. (2006). Protein kinase C delta mediates platelet-induced breast cancer cell invasion. Journal of Pharmacology and Experimental Therapeutics, 318(1), 373–380.PubMedCrossRef
253.
Zhao, L., Lu, G., Zhao, Q., Zhang, M., Chen, M., Zhang, J., & Dai, K. (2015). Staurosporine induces platelet apoptosis through p38 mitogen-activated protein kinase signaling pathway. Clinical Laboratory, 61(7), 717–726.PubMed
254.
Lesyk, G., Fong, T., Ruvolo, P. P., & Jurasz, P. (2015). The potential of enzastaurin to enhance platelet aggregation and growth factor secretion: implications for cancer cell survival. Journal of Thrombosis and Haemostasis, 13(8), 1514–1520.PubMedCrossRef
255.
Fuentes, E., Rojas, A., & Palomo, I. (2016). NF-κB signaling pathway as target for antiplatelet activity. Blood Review, 30(4), 309–315.CrossRef
256.
Chang, C. C., Lu, W. J., Ong, E. T., Chiang, C. W., Lin, S. C., Huang, S. Y., & Sheu, J. R. (2011). A novel role of sesamol in inhibiting NF-κB-mediated signaling in platelet activation. Journal of Biomedical Science, 18, 93.PubMedPubMedCentralCrossRef
257.
Mehta, P., Kimura, A., & Lawson, D. (1990). Effects of calcium channel-blocking agents on platelet-osteogenic sarcoma interaction: platelet aggregation and electron microscopic findings. Journal of Orthopeadic Research, 8(5), 629–634.CrossRef
258.
Dovizio, M., Maier, T. J., Alberti, S., Di Francesco, L., Marcantoni, E., Münch, G., et al. (2013). Pharmacological inhibition of platelet-tumor cell cross-talk prevents platelet-induced overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cells. Molecular Pharmacology, 84(1), 25–40.PubMedCrossRef
259.
Lou, X. L., Sun, J., Gong, S. Q., Yu, X. F., Gong, R., & Deng, H. (2015). Interaction between circulating cancer cells and platelets: clinical implication. Chinese Journal of Cancer Research, 27(5), 450–460.PubMedPubMedCentral
260.
Almiron Bonnin, D. A., Ran, C., Havrda, M. C., Liu, H., Hitoshi, Y., Zhang, Z., et al. (2017). Insulin-mediated signaling facilitates resistance to in proneural hPDGFB-driven gliomas. Molecular Cancer Therapeutics. doi:10.​1158/​1535-7163.​MCT-16-0616.
261.
Heske, C. M., Yeung, C., Mendoza, A., Baumgart, J. T., Edessa, L. D., Wan, X., & Helman, L. J. (2016). The role of PDGFR-β activation in acquired resistance to IGF-1R blockade in preclinical models of rhabdomyosarcoma. Translational Oncology, 9(6), 540–547.PubMedPubMedCentralCrossRef
262.
Kwon, H. J., Kim, G. E., Lee, Y. T., Jeong, M. S., Kang, I., Yang, D., & Yeo, E. J. (2013). Inhibition of platelet-derived growth factor receptor tyrosine kinase and downstream signaling pathways by Compound C. Cellular Signalling, 25(4), 883–897.PubMedCrossRef
263.
Johnson, K. E., Forward, J. A., Tippy, M. D., Ceglowski, J. R., El-Husayni, S., Kulenthirarajan, R., Machlus, K. R., et al. (2017). Tamoxifen directly inhibits platelet Angiogenic potential and platelet-mediated metastasis. Arteriosclerosis, Thrombosis, and Vascular Biology. doi:10.​1161/​ATVBAHA.​116.​308791.
Metadata
Title
Antiplatelet agents for cancer treatment: a real perspective or just an echo from the past?
Authors
Marek Z. Wojtukiewicz
Dominika Hempel
Ewa Sierko
Stephanie C. Tucker
Kenneth V. Honn
Publication date
01-06-2017
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 2/2017
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-017-9683-z

Other articles of this Issue 2/2017

Cancer and Metastasis Reviews 2/2017 Go to the issue

OriginalPaper

Platelet RNA signatures for the detection of cancer

NON-THEMATIC REVIEW

Cleavage and phosphorylation: important post-translational modifications of galectin-3

ReviewPaper

Platelet “first responders” in wound response, cancer, and metastasis

Announcement

Biography—David Menter

OriginalPaper

Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention

NON-THEMATIC REVIEW

Radiation-induced inflammatory cascade and its reverberating crosstalks as potential cause of post-radiotherapy second malignancies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits